多发性硬化症的临床试验研究更新.pdf

1、Research Update:Clinical Trials for Multiple SclerosisAndrew Wolf,MDDepartment of Neurology&Rocky Mountain MS CenterUniversity of Colorado School of MedicineApril 6,2024DisclosuresI have received funding for research from the Rocky Mountain MS Center and the Mowry Family,payments for clinical trials

2、 from Genentech/Roche,consulting fees from TG Therapeutics,and honoraria from MedLink Neurology and Horizon Therapeutics.I have served as a subinvestigator for the FENtrepid(NCT04544449)&FENhance(NCT04586010)studies evaluating the BTK inhibitor fenebrutinib which is directly relevant to todays conte

3、nt on BTK inhibitors.ObjectiveTo discuss recent developments in multiple sclerosis(MS)researchTodays focus will be on novel therapeutics,including the latest clinical trials for potential new disease-modifying therapies(DMTs)First,we will review some basic concepts on MS pathophysiology and drug dev

4、elopmentThen we will focus on two specific areas:Update on Bruton tyrosine kinase(BTK)inhibitor(BTKi)evobrutinib Overview of frexalimab,the first anti-CD40L drug being studied for MSGoals of Treatment in MSOverarching goal is prevention of long-term disabilityDisability accumulates via relapse-assoc

5、iated worsening(RAW)and progression independent of relapse activity(PIRA)Stopping or slowing these process is fundamental to improving outcomesLublin et al.Brain.2022.2017199520002005201020112012Aubagio(teriflunomide)Tecfidera(dimethyl fumarate)Extavia(IFN-1b)Gilenya(fingolimod)Tysabri(natalizumab)B

6、etaseron(IFN-1b)Copaxone(glatiramer acetate)Avonex(IFN-1a)Rebif(IFN-1a)Novantrone(mitoxantrone)20132014Ocrevus(ocrelizumab)Glatiramer acetate 40 mg SC TIWPlegridy (Pegylated IFN-1a)Lemtrada(alemtuzumab)2015/2016Glatopa(glatiramer acetate)MylanGlatiramer acetate201820192020Mayzent(siponimod)Rituxan(r